BR112022010633A2 - Composto de fórmula, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer de tireoide e invenção - Google Patents

Composto de fórmula, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer de tireoide e invenção

Info

Publication number
BR112022010633A2
BR112022010633A2 BR112022010633A BR112022010633A BR112022010633A2 BR 112022010633 A2 BR112022010633 A2 BR 112022010633A2 BR 112022010633 A BR112022010633 A BR 112022010633A BR 112022010633 A BR112022010633 A BR 112022010633A BR 112022010633 A2 BR112022010633 A2 BR 112022010633A2
Authority
BR
Brazil
Prior art keywords
compound
prophylaxis
treatment
pharmaceutical composition
thyroid cancer
Prior art date
Application number
BR112022010633A
Other languages
English (en)
Inventor
Dolente Cosimo
Stephen HEWINGS David
Hunziker Daniel
Krummenacher Daniela
Francesco Tommaso Pettazzoni Piergiorgio
Wichmann Juergen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112022010633A2 publication Critical patent/BR112022010633A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSTO DE FÓRMULA, COMPOSIÇÃO FARMACÊUTICA, USO DE UM COMPOSTO, MÉTODO PARA O TRATAMENTO OU PROFILAXIA DE CÂNCER DE TIREOIDE E INVENÇÃO. A invenção fornece um composto novo que têm a fórmula geral (I) (I) em que R1-R3 e X são conforme definidos no relatório descritivo e nas reivindicações. O composto da fórmula (I) pode ser usado como um medicamento.
BR112022010633A 2019-12-10 2020-12-08 Composto de fórmula, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer de tireoide e invenção BR112022010633A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19214867 2019-12-10
PCT/EP2020/084969 WO2021116050A1 (en) 2019-12-10 2020-12-08 New braf inhibitors as paradox breakers

Publications (1)

Publication Number Publication Date
BR112022010633A2 true BR112022010633A2 (pt) 2022-08-16

Family

ID=68848068

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010633A BR112022010633A2 (pt) 2019-12-10 2020-12-08 Composto de fórmula, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer de tireoide e invenção

Country Status (18)

Country Link
US (1) US20220298145A1 (pt)
EP (1) EP4073044A1 (pt)
JP (1) JP2023505300A (pt)
KR (1) KR20220112777A (pt)
CN (1) CN114746405B (pt)
AR (1) AR120697A1 (pt)
AU (1) AU2020403082A1 (pt)
BR (1) BR112022010633A2 (pt)
CA (1) CA3158541A1 (pt)
CL (1) CL2022001492A1 (pt)
CO (1) CO2022007621A2 (pt)
CR (1) CR20220252A (pt)
IL (1) IL292349A (pt)
MX (1) MX2022006711A (pt)
PE (1) PE20221027A1 (pt)
TW (1) TW202136218A (pt)
WO (1) WO2021116050A1 (pt)
ZA (1) ZA202204092B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY161576A (en) * 2008-03-17 2017-04-28 Ambit Biosciences Corp Quinazoline derivatives as raf kinase modulators and methods of use thereof
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
CN104640865B (zh) * 2012-09-19 2018-05-11 诺华股份有限公司 作为激酶抑制剂的二氢吡咯烷子基-嘧啶
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
MX2022015703A (es) * 2020-06-09 2023-01-24 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.

Also Published As

Publication number Publication date
CO2022007621A2 (es) 2022-08-30
CR20220252A (es) 2022-07-11
IL292349A (en) 2022-06-01
KR20220112777A (ko) 2022-08-11
CN114746405A (zh) 2022-07-12
CL2022001492A1 (es) 2023-02-24
AR120697A1 (es) 2022-03-09
ZA202204092B (en) 2022-12-21
US20220298145A1 (en) 2022-09-22
JP2023505300A (ja) 2023-02-08
AU2020403082A1 (en) 2022-05-12
CN114746405B (zh) 2024-03-26
EP4073044A1 (en) 2022-10-19
CA3158541A1 (en) 2021-06-17
WO2021116050A1 (en) 2021-06-17
TW202136218A (zh) 2021-10-01
PE20221027A1 (es) 2022-06-16
MX2022006711A (es) 2022-07-12

Similar Documents

Publication Publication Date Title
BR112015032595A2 (pt) inibidores de ido
BR112018007395A2 (pt) 2,4-di-hidróxi-nicotinamidas como agonistas de apj
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
BR112021026498A2 (pt) Composto, uso do composto e composição farmacêutica
BR112022001341A2 (pt) Inibidores de enzima
BR112022009938A2 (pt) Compostos macrocíclicos substituídos e métodos de tratamento relacionados
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112022011123A2 (pt) Composto, processo para a preparação de um composto, usos de um composto, métodos para o tratamento de câncer e invenção
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
BR112022008365A2 (pt) Inibidores de cd73
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
BR112014018670A8 (pt) Compostos de fórmula, composição farmacêutica, uso de um composto, método para o tratamento e invenção
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
BR112022003799A2 (pt) Compostos antibacterianos
BR112018007068A2 (pt) derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta
BR112017018198A2 (pt) inibição da atividade de olig2
CR20230500A (es) Métodos para inhibir ras
MX2021001612A (es) Compuestos utiles en terapia del vih.